Summary

Eligibility
for people ages 5 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Lynda Polgreen, MD (ucla)

Description

Summary

Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

Official Title

Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI

Details

This study is a randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI. Children and adults diagnosed with MPS I, II or VI, with significant joint restrictions and pain will be randomized to adalimumab treatment or placebo treatment for the first 16 weeks. This will be followed by a 32-week open label adalimumab treatment phase.

Keywords

Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI, Mucopolysaccharidoses, Adalimumab, Adalimumab Injection [Humira], Saline Solution for Injection, Open-label adalimumab

Eligibility

You can join if…

Open to people ages 5 years and up

  • Male or female ≥5 years of age;
  • Diagnosis of MPS I, II or VI;
  • Treatment with ERT for ≥1 year or no treatment with ERT for ≥1 year;
  • Weight ≥15 kg;
  • Significant bodily pain reported by the CHQ-PF50 or SF-36 (> 1 SD more severe [below] than the general population mean);
  • ≥ 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.

You CAN'T join if...

  • History of HCT less than 2 years prior to enrollment;
  • Immune suppression therapy less than 1 year prior to enrollment;
  • Active graft versus host disease;
  • Current diagnosis or history of lymphoma or other malignancy;
  • Current active infection;
  • History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);
  • Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB
  • Congestive heart failure defined by an ejection fracture <50% measured by ECHO;
  • Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome);
  • Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);
  • Hepatitis B infection (active or chronic carrier);
  • Latex sensitivity;
  • Pregnancy or breastfeeding;
  • Known or suspected allergy to adalimumab or related products;
  • Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;
  • Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or
  • Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.

Location

  • The Lundquist Institute at Harbor-UCLA Medical Center
    Torrance California 90502 United States

Lead Scientist at University of California Health

  • Lynda Polgreen, MD (ucla)
    Associate Professor-in-Residence, Pediatrics, Medicine. Authored (or co-authored) 62 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
ID
NCT03153319
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 14 study participants
Last Updated